Reyner, Daniel
AstraZeneca (United States)
2 papers on CoChat
Most cited papers
- Verified
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial
Pollock, C., Stefánsson, B., Reyner, D., Rossing, P., Sjöström, C. D., Wheeler, D. C., Langkilde, A. M., & Heerspink, H. J. L. (2019) · The Lancet Diabetes & Endocrinology
Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes
Cited by 205
- Verified
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3a): the DERIVE Study
Fioretto, P., Del Prato, S., Buse, J. B., Goldenberg, R., Giorgino, F., Reyner, D., Langkilde, A. M., Sjöström, C. D., Sartipy, P., & On Behalf of the DERIVE Study Investigators (2018) · Diabetes, Obesity and Metabolism
Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes
Cited by 195
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free